BIIB

SEC source: 0001127602-23-004577 · form4.xml · derivative · entry 2

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,905

Underlying: Common Stock · 4,905 shares

Expires 2026-02-08

F1 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 02/08/2023.

SEC source: 0001127602-23-004573 · form4.xml · derivative · entry 2

ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,570

Underlying: Common Stock · 6,570 shares

Expires 2026-02-08

F1 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 2/8/2023.

SEC source: 0001127602-23-003460 · form4.xml · derivative · entry 2

Singhal Priya · CIK 0001769608 · Head of Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,485

Underlying: Common Stock · 5,485 shares

Expires 2026-02-01

F1 · derivative.exercise_date: This award was granted to the reporting person on February 1, 2023 and will vest in three equal installments on each anniversary of the grant date.

SEC source: 0001127602-23-002487 · form4.xml · nonDerivative · entry 1

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,098.7483

F1 · shares: Represents shares earned upon satisfaction of certain performance conditions associated with performance stock units granted on February 12, 2020. The shares will vest on February 12, 2023.

SEC source: 0001127602-23-002485 · form4.xml · nonDerivative · entry 1

Singhal Priya · CIK 0001769608 · Head of Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,652.3923

F1 · shares: Represents shares earned upon satisfaction of certain performance conditions associated with performance stock units granted on March 2, 2020. The shares will vest on March 2, 2023.

SEC source: 0001127602-23-002483 · form4.xml · nonDerivative · entry 1

Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,108.2903

F1 · shares: Represents shares earned upon satisfaction of certain performance conditions associated with performance stock units granted on February 12, 2020. The shares will vest on February 12, 2023.

SEC source: 0001127602-23-002479 · form4.xml · nonDerivative · entry 1

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,163.0168

F1 · shares: Represents shares earned upon satisfaction of certain performance conditions associated with performance stock units granted on February 12, 2020. The shares will vest on February 12, 2023.

SEC source: 0001127602-23-002481 · form4.xml · nonDerivative · entry 1

Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,844

F1 · shares: Represents shares earned upon satisfaction of certain performance conditions associated with performance stock units granted on February 12, 2020. The shares will vest on February 12, 2023.

SEC source: 0001127602-23-002477 · form4.xml · nonDerivative · entry 1

ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,099

F1 · shares: Represents shares earned upon satisfaction of certain performance conditions associated with performance stock units granted on February 12, 2020. The shares will vest on February 12, 2023.

SEC source: 0001127602-22-027340 · form4.xml · derivative · entry 3

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 702

Underlying: Common Stock · 350 shares

Expires 2024-12-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing on the first anniversary of the grant date of 12/8/2021.

SEC source: 0001127602-22-027340 · form4.xml · nonDerivative · entry 2

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,211.7483

SEC source: 0001127602-22-027340 · form4.xml · nonDerivative · entry 1

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,367.7483

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-22-026993 · form4.xml · derivative · entry 7

Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 433 shares

Expires 2022-12-02

F2 · date: This award was granted to the reporting person on December 2, 2019. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

F2 · derivative.exercise_date: This award was granted to the reporting person on December 2, 2019. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

F3 · derivative.exercise_date: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

SEC source: 0001127602-22-026993 · form4.xml · derivative · entry 6

Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 433

Underlying: Common Stock · 425 shares

Expires 2022-12-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This award was granted to the reporting person on December 2, 2019. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-22-026993 · form4.xml · derivative · entry 5

Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,285 shares

Expires 2022-12-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This award was granted to the reporting person on December 2, 2019, and vested in full on December 2, 2022.

SEC source: 0001127602-22-026993 · form4.xml · nonDerivative · entry 4

Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,061

SEC source: 0001127602-22-026993 · form4.xml · nonDerivative · entry 3

Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,250

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-22-026993 · form4.xml · nonDerivative · entry 2

Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,825

SEC source: 0001127602-22-026993 · form4.xml · nonDerivative · entry 1

Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,395

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-22-026992 · form4.xml · derivative · entry 3

Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 131 shares

Expires 2022-12-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This award was granted to the reporting person on December 2, 2019 and vested in three equal installments on each anniversary of the grant date.

SEC source: 0001127602-22-026992 · form4.xml · nonDerivative · entry 2

Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,768.2903

SEC source: 0001127602-22-026992 · form4.xml · nonDerivative · entry 1

Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,807.2903

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-22-026909 · form4.xml · derivative · entry 3

Viehbacher Christopher · CIK 0001774478 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,998

Underlying: Common Stock · 45,998 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Performance Stock Unit ("PSU") or Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of common stock.

F4 · derivative.exercise_date: This represents the reporting person's PSUs that will be eligible for vesting based on achievement of absolute stock price compound annual growth rate goals ("Absolute CAGR PSUs") over a three-year performance period ending on November 30, 2025. The number of Absolute CAGR PSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout.

F4 · derivative.expiration_date: This represents the reporting person's PSUs that will be eligible for vesting based on achievement of absolute stock price compound annual growth rate goals ("Absolute CAGR PSUs") over a three-year performance period ending on November 30, 2025. The number of Absolute CAGR PSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout.

SEC source: 0001127602-22-026909 · form4.xml · derivative · entry 2

Viehbacher Christopher · CIK 0001774478 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,040

Underlying: Common Stock · 7,040 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Performance Stock Unit ("PSU") or Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of common stock.

F3 · derivative.exercise_date: Each RSU is eligible to vest on the third anniversary of the grant date of December 1, 2022.

F3 · derivative.expiration_date: Each RSU is eligible to vest on the third anniversary of the grant date of December 1, 2022.

SEC source: 0001127602-22-026909 · form4.xml · derivative · entry 1

Viehbacher Christopher · CIK 0001774478 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,522

Underlying: Common Stock · 80,522 shares

Expires 2032-12-01

F1 · derivative.exercise_date: The Stock Options are eligible to vest and become exercisable in approximately equal annual installments on the first, second and third anniversaries of the grant date of December 1, 2022.

SEC source: 0001127602-23-002502 · form5.xml · nonDerivative · entry 1

SHERWIN STEPHEN A · CIK 0001079462 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,778

SEC source: 0001127602-22-027348 · form4.xml · nonDerivative · entry 1

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,711.0168

F1 · kind: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2 · balance_after: Includes 102.4003 shares acquired under the Biogen Inc. employee stock purchase plan on 3/31/2022.

SEC source: 0001127602-22-024470 · form4.xml · nonDerivative · entry 1

ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,396

F1 · kind: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

SEC source: 0001127602-22-022132 · form4.xml · derivative · entry 7

MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,366

Underlying: Common Stock · 3,298 shares

Expires 2023-09-01

F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).

F3 · derivative.exercise_date: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

SEC source: 0001127602-22-022132 · form4.xml · derivative · entry 6

MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,664

Underlying: Common Stock · 2,064 shares

Expires 2023-09-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).

SEC source: 0001127602-22-022132 · form4.xml · derivative · entry 5

MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,682

Underlying: Common Stock · 2,682 shares

Expires 2023-09-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 09/01/2020.

SEC source: 0001127602-22-022132 · form4.xml · nonDerivative · entry 4

MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,745

SEC source: 0001127602-22-022132 · form4.xml · nonDerivative · entry 3

MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,801

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).

SEC source: 0001127602-22-022132 · form4.xml · nonDerivative · entry 2

MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,737

SEC source: 0001127602-22-022132 · form4.xml · nonDerivative · entry 1

MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,109

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 09/01/2020.

SEC source: 0001127602-22-020415 · form4.xml · derivative · entry 7

Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 825 shares

Expires 2022-08-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: This award was granted to the reporting person on August 1, 2019 and vested in full on August 1, 2022.

SEC source: 0001127602-22-020415 · form4.xml · derivative · entry 6

Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 255 shares

Expires 2022-08-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This award was granted to the reporting person on August 1, 2019. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times (the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date)).

SEC source: 0001127602-22-020415 · form4.xml · derivative · entry 5

Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 255

Underlying: Common Stock · 299 shares

Expires 2022-08-01

F2 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F3 · derivative.exercise_date: This award was granted to the reporting person on August 1, 2019. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times (the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date)).

SEC source: 0001127602-22-020415 · form4.xml · nonDerivative · entry 4

Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,676.2903

SEC source: 0001127602-22-020415 · form4.xml · nonDerivative · entry 3

Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,919.2903

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-22-020415 · form4.xml · nonDerivative · entry 2

Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,094.2903

SEC source: 0001127602-22-020415 · form4.xml · nonDerivative · entry 1

Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,170.2903

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 102.4003 shares acquired under the Biogen Inc. employee stock purchase plan.

SEC source: 0001127602-22-019021 · form4.xml · derivative · entry 3

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 252

Underlying: Common Stock · 252 shares

Expires 2023-07-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 07/01/2020.

SEC source: 0001127602-22-019021 · form4.xml · nonDerivative · entry 2

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,017.7483

SEC source: 0001127602-22-019021 · form4.xml · nonDerivative · entry 1

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,091.7483

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 102.4003 shares acquired under the Biogen Inc. employee stock purchase plan.

SEC source: 0001127602-22-019020 · form4.xml · derivative · entry 3

Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 504

Underlying: Common Stock · 504 shares

Expires 2024-07-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This award was granted to the reporting person on July 1, 2020, and will vest in three equal installments on each anniversary of the grant date.

SEC source: 0001127602-22-019020 · form4.xml · nonDerivative · entry 2

Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,110

SEC source: 0001127602-22-019020 · form4.xml · nonDerivative · entry 1

Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,258

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-22-017811 · form4.xml · nonDerivative · entry 1

SHERWIN STEPHEN A · CIK 0001079462 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,473

SEC source: 0001127602-22-017806 · form4.xml · nonDerivative · entry 1

PAPADOPOULOS STELIOS · CIK 0001202098 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,095